GEN Exclusives

More »

GEN News Highlights

More »
Jun 3, 2008

GSK and the Immune Disease Institute in Boston Sign Five-Year $25M Collaboration

  • GlaxoSmithKline (GSK) signed a five-year collaboration with the Immune Disease Institute in Boston (IDI) worth $25M to accelerate research in immunoinflammation.

    IDI’s immunological expertise will be combined with GSK’s pharmaceutical capabilities. This partnership allows researchers at both institutions to develop joint grant proposals under what will be called the Alliance Research grant program.

    Additionally, GSK receives an exclusive right of first negotiation for a substantial portion of the new technologies discovered and disclosed by IDI scientists during the term of the agreement. The research will be anchored through GSK’s Immuno-Inflammation Centre of Excellence in Drug Discovery.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?